Gerischer, L., Schroeder‐Braunstein, J., Wabnitz, G., & Meisel, A. (2026). Reply to Letter: "Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring" by Saccà and Pelto Regarding "Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab". Annals of Clinical & Translational Neurology, 13(6), 1303. https://doi.org/10.1002/acn3.70403
Chicago Style (17th ed.) CitationGerischer, Lea, Jutta Schroeder‐Braunstein, Guido Wabnitz, and Andreas Meisel. "Reply to Letter: "Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring" by Saccà and Pelto Regarding "Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab"." Annals of Clinical & Translational Neurology 13, no. 6 (2026): 1303. https://doi.org/10.1002/acn3.70403.
MLA (9th ed.) CitationGerischer, Lea, et al. "Reply to Letter: "Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring" by Saccà and Pelto Regarding "Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab"." Annals of Clinical & Translational Neurology, vol. 13, no. 6, 2026, p. 1303, https://doi.org/10.1002/acn3.70403.
